Byline: Carrie LaFrenz Nov 15, 2012 (The Australian Financial Review - ABIX via COMTEX) -- The stock of Australian-listed biotechnology group Mesoblast on 15 November 2012 closed $A0.24 lower at $A5.12, but early in the session had dropped rapidly to as little as $A4.22. CEO Silviu Itescu blames ... (Publication: Australasian Business Intelligence)
↧